Therini Bio® is developing novel therapeutics based on unique insights into the novel role of fibrin in driving chronic innate immune activation that characterizes a broad set of human diseases with high unmet need.

Fibrin deposition and impaired fibrinolysis has long been implicated as a driver of chronic inflammation secondary to loss of vascular integrity in a large number of central nervous system (CNS) and peripheral inflammatory diseases. However, a lack of understanding of the cellular and molecular innate immune mechanisms responsible for fibrin-driven inflammation and an inability to target the inflammatory aspects of fibrin, while sparing any downstream impact on its role in hemostasis has prevented therapeutic intervention along this axis.